The startup develops a diagnostic kit that utilizes prognostic testing to accurately assess the risk and progression of melanoma in patients at early AJCC Stage I and Stage II. This technology enables targeted treatment stratification and reduces unnecessary patient surveillance, ultimately alleviating psychological stress for patients and saving health authorities significant costs.

Pneumagen is developing Neumifil, a multivalent Carbohydrate Binding Module (mCBM) designed for the prophylaxis and treatment of viral respiratory tract infections, including influenza and coronaviruses. This targeted approach addresses the significant medical need for effective prevention of viral-induced exacerbations in patients with chronic respiratory diseases, which can lead to increased morbidity and healthcare costs.

Reconnect Labs develops precision neuropsychiatric therapeutics and predictive diagnostics targeting insomnia, anxiety, and substance use disorders. Their platform combines engineered psychoactive formulations with disease‑modifying mechanisms to deliver both rapid symptom relief and long‑term therapeutic benefit. Leveraging expertise in neuroscience, psychopharmacology, and clinical research, they aim to create scalable, cost‑effective treatments for mental health conditions.

Spiral Therapeutics develops a minimally invasive cochlear drug delivery platform, MICS™, to administer sustained-release steroid formulations directly to the inner ear for the treatment of Ménière’s disease. This approach addresses the lack of FDA-approved therapies for hearing loss by providing targeted, long-lasting drug exposure to manage vertigo and other symptoms effectively.